In an ongoing Phase II study, ISTH0036 has shown potential in reducing fibrosis and fluid volumes in treatment-naïve and anti-VEGF-pretreated patients with wet AMD and DME. The gene discussed is VEGFA; the disease is wet macular degeneration.